Frontiers in Endocrinology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2023-10-30 791313987 来自江苏省

感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧...

326 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2023-01-12 ms5000001329361729 来自河南省

目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision.
请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们

393 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2024-11-30 ms2000002146747069 来自山西省

文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊

16 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2024-11-06 匿名用户

此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项

39 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2024-10-18 chjie999 来自广东省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：内分泌;糖尿病
经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀

41 0

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2023-08-07 嗯啊啊来自北京

审稿速度:24.0 | 投稿命中率:50.0
经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。

112 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2024-08-27 148975dam71暂无昵称来自北京

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：生殖内分泌
经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了

72 0

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2022-12-15 大仑丁来自湖北省

审稿速度:1.0
偏重的研究方向：糖尿病
经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final.

387 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2024-06-05 我要毕业2024 来自广东省

请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？

262 0

[GetPortalCommentsPageByObjectIdResponse(id=2165820, encodeId=716c2165820b0, content=感觉最近有点慢啊，卡在Editorial Assignment半个月了，丝毫没有动静，编辑们都去休假了吗？也还没到圣诞节吧..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230220/b6e40eea2fa5422ea67ef0e7c3b2e44b/808d8afa8f4d42fea20d07f572948bcf.jpg, createdBy=f8553109256, createdName=791313987, createdTime=Mon Oct 30 23:31:00 CST 2023, time=2023-10-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2109972, encodeId=b8e921099e22f, content=目前只有两个审稿人审稿，建议接受。现在状态变成The Associate Editor XX is evaluating any revisions made to the manuscript to take a final decision. 请问各位大佬还会继续邀请审稿人吗？这个状态会持续多久呀？谢谢你们 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=393, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1528458531, createdName=ms5000001329361729, createdTime=Thu Jan 12 16:16:25 CST 2023, time=2023-01-12, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2240016, encodeId=19e6224001696, content=文章修改后，之前一审的一个审稿人一直不复审稿，多久会找新的审稿人啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d95692568, createdName=ms2000002146747069, createdTime=Sat Nov 30 01:09:32 CST 2024, time=2024-11-30, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2235453, encodeId=b2fc22354535c, content=此期刊不再接收原创研究，稿约及投稿系统均删除了原创研究的选项, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Wed Nov 06 09:02:47 CST 2024, time=2024-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2231636, encodeId=16cf22316363c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：内分泌;糖尿病 经验分享：投稿45天终于得到了修稿意见。修稿要求5天内返稿。返完很快就给了接收的意见了。有一点值得一提的是，被接收了之后收到了诈骗邮件，骗万博manbetx登录去别的地方给版面费。切记警惕。注意观察邮箱后缀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de691645265, createdName=chjie999, createdTime=Fri Oct 18 22:14:43 CST 2024, time=2024-10-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2151587, encodeId=7a87215158ede, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：慎投吧，太不讲信用了。交了版面费之后3个月了还不online，问就是官方回复让等，就是一直拖着想让作者自己撤回。。。吃相难看。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/C74E2CBF647CA3DABA6723C9FBF387AD/100, createdBy=e88f2200779, createdName=嗯啊啊, createdTime=Mon Aug 07 10:28:44 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222724, encodeId=f35e2222e24b7, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生殖内分泌 经验分享：朋友们，此期刊会进预警吗，浙大已经把frontiers全挂进预警了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c8b85315215, createdName=148975dam71暂无昵称, createdTime=Tue Aug 27 21:33:27 CST 2024, time=2024-08-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=387, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208458, encodeId=124522084581c, content=请问这个期刊申请减免版面费的话成功率高么？会不会影响文章录用？通常文章什么状态的时候申请？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72dd5503770, createdName=我要毕业2024, createdTime=Wed Jun 05 15:54:27 CST 2024, time=2024-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198626, encodeId=15f5219862674, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：生殖医学 经验分享：15 Apr 2024 Article accepted for publication. 10 Apr 2024 Review of Review Editor 3 finalized. 04 Apr 2024 You posted new comments. Reviewer 3 posted new comments. 28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript. 14 Mar 2024 Interactive review forum activated. 25 Jan 2024 Review of Reviewer 1 is finalized. 23 Nov 2023 Corresponding Author Chen Wang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202410/c3d1441566c54e84879e4a79d0ec1ab7-VTvkhXxvQdFE.jpg, createdBy=ed3c2532598, createdName=125051b5m55(暂无昵称), createdTime=Mon Apr 15 15:36:02 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省)]

2024-04-15 125051b5m55(暂无昵称) 来自湖南省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：生殖医学
经验分享：15 Apr 2024 Article accepted for publication.
10 Apr 2024 Review of Review Editor 3 finalized.
04 Apr 2024 You posted new comments. Reviewer 3 posted new comments.
28 Mar 2024 Corresponding Author Chen Wang re-submitted manuscript.
14 Mar 2024 Interactive review forum activated.
25 Jan 2024 Review of Reviewer 1 is finalized.
23 Nov 2023 Corresponding Author Chen Wang submitted manuscript.

297 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务